Cellectis (NASDAQ: CLLS) reported Q2 EPS of ($0.80), $0.29 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $14.62 million versus the consensus estimate of $23.46 million.

For earnings history and earnings-related data on Cellectis (CLLS) click here.